| |
| |
|
| Insider
Information: |
Shanmugam Muthusamy |
| Relationship: |
HEAD OF R&D, COO-NOVIT... |
| City: |
Baudette |
| State: |
MN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,652 |
|
|
Indirect Shares
|
787,620 |
|
|
| Direct
Value |
$4,616,847 |
|
|
|
Indirect Value
|
$52,967,445 |
|
|
| Total
Shares |
856,272 |
|
|
| Total
Value |
$57,584,292 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
ANI Pharmaceuticals Inc |
ANIP |
HEAD OF R&D, COO-NOVIT... |
2024-04-19 |
68,652 |
2024-04-19 |
787,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
54 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2022-03-17 |
4 |
B |
$27.65 |
$138,252 |
D/D |
5,000 |
18,460 |
0.01 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2022-03-17 |
4 |
B |
$27.65 |
$138,252 |
I/I |
5,000 |
5,000 |
0.01 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-20 |
4 |
AS |
$51.93 |
$761,138 |
D/D |
(14,657) |
32,750 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-20 |
4/A |
AS |
$51.93 |
$761,138 |
I/I |
(14,657) |
1,317,963 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-21 |
4 |
AS |
$51.95 |
$615,244 |
D/D |
(11,843) |
20,907 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-21 |
4/A |
AS |
$51.95 |
$615,244 |
I/I |
(11,843) |
1,306,120 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-22 |
4/A |
AS |
$51.38 |
$693,630 |
I/I |
(13,500) |
1,292,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-22 |
4 |
AS |
$51.38 |
$693,630 |
D/D |
(13,500) |
7,407 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-06-23 |
4/A |
AS |
$51.49 |
$514,900 |
I/I |
(10,000) |
1,282,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-14 |
4 |
AS |
$50.43 |
$504,300 |
I/I |
(10,000) |
1,272,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-17 |
4 |
AS |
$51.06 |
$501,971 |
I/I |
(9,831) |
1,262,789 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-18 |
4 |
AS |
$51.84 |
$347,328 |
I/I |
(6,700) |
1,256,089 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-19 |
4 |
AS |
$51.48 |
$307,284 |
I/I |
(5,969) |
1,250,120 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-20 |
4 |
AS |
$51.52 |
$309,120 |
I/I |
(6,000) |
1,244,120 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-21 |
4 |
AS |
$52.56 |
$604,440 |
I/I |
(11,500) |
1,232,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-14 |
4 |
AS |
$61.15 |
$1,705,474 |
I/I |
(27,890) |
1,204,730 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-15 |
4 |
AS |
$61.60 |
$1,361,976 |
I/I |
(22,110) |
1,182,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-28 |
4 |
S |
$63.06 |
$1,576,500 |
I/I |
(25,000) |
1,157,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-29 |
4 |
S |
$63.37 |
$1,584,250 |
I/I |
(25,000) |
1,132,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-15 |
4 |
AS |
$62.81 |
$1,020,160 |
I/I |
(16,242) |
1,116,378 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-18 |
4 |
AS |
$61.64 |
$519,317 |
I/I |
(8,425) |
1,107,953 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-19 |
4 |
AS |
$61.23 |
$1,551,140 |
I/I |
(25,333) |
1,082,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-13 |
4 |
AS |
$57.58 |
$687,332 |
I/I |
(11,937) |
1,070,683 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-16 |
4 |
AS |
$58.31 |
$761,704 |
I/I |
(13,063) |
1,057,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-17 |
4 |
AS |
$58.53 |
$512,606 |
I/I |
(8,758) |
1,048,862 |
0 |
- |
|
54 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
